The FDA has cleared an expanded indication for Medtronic’s Solitaire stent retriever device.

The FDA now allows the marketing of the Solitaire device as an initial therapy for acute ischemic strokes for patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts to reduce paralysis, speech difficulties and other stroke-related disabilities.

statement from Medtronic
article in Fierce Biotech